Exclusive: Feng Zhang CRISPR startup gathers patents, locking up rights to family of editing tech
In the bid to lock up patent rights to a growing suite of gene editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT scientist and CRISPR pioneer Feng Zhang, the company exclusively told Endpoints News.
Zhang’s startup, Serendipity Bioscience, has never disclosed how much funding it raised, and Arbor — which Zhang also co-founded — wouldn’t say how much it paid. But Arbor now holds the keys to four new families of gene editing enzymes discovered in Zhang’s lab in recent years, each the subject of major scientific publications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
